-
公开(公告)号：US20200079835A1
公开(公告)日：2020-03-12
申请号：US16516225
申请日：2019-07-18
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Glen Eugene Mikesell , Han Chang , Joshua N. Finger , Guchen Yang , Robert James Peach , Henry Shen
IPC: C07K14/705 , C07K16/28
Abstract: The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject.
-
公开(公告)号：US20190248868A1
公开(公告)日：2019-08-15
申请号：US16382620
申请日：2019-04-12
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Glen Eugene Mikesell , Han Chang , Robert James Peach
IPC: C07K14/705 , G01N33/50 , C07K16/28 , A61K39/395 , A61K38/17 , C07K19/00
CPC classification number: C07K14/70532 , A61K38/00 , A61K38/1774 , A61K39/39533 , A61K2039/505 , C07K16/2827 , C07K19/00 , C07K2317/56 , C07K2317/73 , C07K2317/76 , C07K2319/00 , C07K2319/02 , C07K2319/03 , C07K2319/10 , C07K2319/30 , C07K2319/40 , G01N33/5005 , Y02A50/396
Abstract: The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject.
-
公开(公告)号：US20130144042A1
公开(公告)日：2013-06-06
申请号：US13711855
申请日：2012-12-12
Applicant: Bristol-Myers Squibb Company
Inventor： Glen Eugene Mikesell , Henry Shen , Han Chang , Joshua N. Finger , Guchen Yang , Robert James Peach
IPC: C07K19/00
CPC classification number: C07K14/70532 , A61K38/00 , A61K38/1774 , A61K39/39533 , A61K2039/505 , C07K16/2827 , C07K19/00 , C07K2317/56 , C07K2317/73 , C07K2317/76 , C07K2319/00 , C07K2319/02 , C07K2319/03 , C07K2319/10 , C07K2319/30 , C07K2319/40 , G01N33/5005 , Y02A50/396
Abstract: The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject.
Abstract translation: 本发明提供编码调节免疫或炎性反应细胞如T细胞活化的B7相关因子的核酸。 还提供了包含编码B7相关多肽（包括BSL1，BSL2和BSL3）的核酸的表达载体和融合构建体。 本发明进一步提供分离的B7相关多肽，分离的包含B7相关多肽的融合蛋白，以及与B7相关多肽特异性反应的抗体或其部分。 此外，本发明提供利用B7相关核酸，多肽或肽的测定法。 本发明还提供可用于人或动物受试者的免疫调节的B7相关核酸，多肽，融合蛋白或抗体的组合物。
-
公开(公告)号：US10308702B2
公开(公告)日：2019-06-04
申请号：US15218699
申请日：2016-07-25
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Glen Eugene Mikesell , Han Chang , Robert James Peach
IPC: C07K14/705 , C07K16/28 , C07K19/00 , A61K38/17 , A61K39/395 , G01N33/50 , A61K38/00 , A61K39/00
Abstract: The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject.
-
公开(公告)号：US09644032B2
公开(公告)日：2017-05-09
申请号：US15166114
申请日：2016-05-26
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Zhehong Cai , Indrani Chakraborty , Marie-Michelle Navarro Garcia , Thomas D. Kempe , Alan J. Korman , Alexander T. Kozhich , Hadia Lemar , Mark Maurer , Christina Maria Milburn , Michael Quigley , Xiang Shao , Mohan Srinivasan , Kent Thudium , Susan Chien-Szu Wong , Jochem Gokemeijer , Xi-Tao Wang , Han Chang , Patrick Guirnalda
IPC: C07K16/28 , A61K39/395 , C07K16/30 , A61K39/00
CPC classification number: C07K16/2878 , A61K39/3955 , A61K2039/505 , A61K2039/507 , A61P35/00 , C07K16/2818 , C07K16/30 , C07K16/3023 , C07K16/3038 , C07K16/3069 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/74 , C07K2317/75 , C07K2317/76 , C07K2317/92 , C07K2317/94 , G01N33/574
Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40. Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
-
Patent Agency Ranking
公开(公告)号：US20200369744A1
公开(公告)日：2020-11-26
申请号：US16778159
申请日：2020-01-31
Applicant: Bristol-Myers Squibb Company
Inventor： Glen Eugene Mikesell , Han Chang , Robert James Peach
IPC: C07K14/705 , C07K16/28 , C07K19/00 , A61K38/17 , A61K39/395 , G01N33/50
Abstract: The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject.
-
公开(公告)号：US09409970B2
公开(公告)日：2016-08-09
申请号：US14178360
申请日：2014-02-12
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Glen Eugene Mikesell , Han Chang , Joshua N. Finger , Guchen Yang , Robert James Peach , Henry Shen
IPC: C07H21/04 , C07K14/705 , C07K16/28 , A61K47/48 , A61K38/00
CPC classification number: C07K14/70532 , A61K38/00 , C07K16/2827 , C07K2317/56 , C07K2317/76 , C07K2319/00 , C07K2319/30 , Y10S435/81
Abstract: The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject.
Abstract translation: 本发明提供编码调节免疫或炎性反应细胞如T细胞活化的B7相关因子的核酸。 还提供了包含编码B7相关多肽（包括BSL1，BSL2和BSL3）的核酸的表达载体和融合构建体。 本发明进一步提供分离的B7相关多肽，分离的包含B7相关多肽的融合蛋白，以及与B7相关多肽特异性反应的抗体或其部分。 此外，本发明提供利用B7相关核酸，多肽或肽的测定法。 本发明还提供可用于人或动物受试者的免疫调节的B7相关核酸，多肽，融合蛋白或抗体的组合物。
-
公开(公告)号：US20240190963A1
公开(公告)日：2024-06-13
申请号：US18468097
申请日：2023-09-15
Applicant: Bristol-Myers Squibb Company
Inventor： Prabhu Seshaiyer Bhagavatheeswaran , Nicholas Allan John Botwood , Han Chang , Yali Fu , William J. Geese , George A. Green, IV , Diane Healey , Sabine Maier , Faith E. Nathan , Abderrahim Oukessou , Giovanni Selvaggi , Joseph Daniel Szustakowski
CPC classification number: C07K16/2818 , A61P35/00 , C07K16/2827 , C07K16/30 , A61K2039/507 , A61K2039/545 , C07K2317/76
Abstract: The disclosure provides a method for treating a subject afflicted with a tumor derived from a non-small cell lung cancer (NSCLC) comprising administering to the subject a therapeutically effective amount of (a) an anti-PD-1 antibody or antigen-binding portion thereof or an anti-PD-L1 antibody or antigen-binding portion thereof and (b) an anti-CTLA-4 antibody or an antigen binding portion thereof, wherein the tumor has a high tumor mutation burden (TMB) status. The TMB status can be determined by sequencing nucleic acids in the tumor and identifying a genomic alteration, e.g., a somatic nonsynonymous mutation, in the sequenced nucleic acids.
-
公开(公告)号：US11466092B2
公开(公告)日：2022-10-11
申请号：US16847130
申请日：2020-04-13
Applicant: Bristol-Myers Squibb Company
Inventor： Zhehong Cai , Indrani Chakraborty , Marie-Michelle Navarro Garcia , Thomas D. Kempe , Alan J. Korman , Alexander T. Kozhich , Hadia Lemar , Mark Maurer , Christina Maria Milburn , Michael Quigley , Xiang Shao , Mohan Srinivasan , Kent Thudium , Susan Chien-Szu Wong , Jochem Gokemeijer , Xi-Tao Wang , Han Chang , Patrick Guirnalda
IPC: A61K39/00 , A61K39/395 , G01N33/53 , C07K16/28 , C07K16/30 , A61P35/00 , G01N33/574
Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40. Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
-
公开(公告)号：US20210032344A1
公开(公告)日：2021-02-04
申请号：US17044163
申请日：2019-03-29
Applicant: Bristol-Myers Squibb Company
Inventor： Prabhu Seshaiyer Bhagavatheeswaran , Nicholas Allan John Botwood , Han Chang , Yali Fu , William J. Geese , George A. Green, IV , Diane Healey , Sabine Maier , Faith E. Nathan , Abderrahim Oukessou , Giovanni Selvaggi , Joseph Daniel Szustakowski
Abstract: The disclosure provides a method for treating a subject afflicted with a tumor derived from a non-small cell lung cancer (NSCLC) comprising administering to the subject a therapeutically effective amount of (a) an anti-PD-1 antibody or antigen-binding portion thereof or an anti-PD-L1 antibody or antigen-binding portion thereof and (b) an anti-CTLA-4 antibody or an antigen binding portion thereof, wherein the tumor has a high tumor mutation burden (TMB) status. The TMB status can be determined by sequencing nucleic acids in the tumor and identifying a genomic alteration, e.g., a somatic nonsynonymous mutation, in the sequenced nucleic acids.
-
-
-
-
-
-
-
-
-
Search Results
19
records
(took 0.045 seconds)
